Cochrane Review Group

Gut

172 systematic reviews in Gut ask 2,395 questions. 17.5% have no studies to answer them, 34.3% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

172

Questions

2,395

current versions

No studies

17.5%

Moderate or high

20.6%

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gut

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.79 [0.37, 1.68]	1 study · 140 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 1.01 [0.65, 1.57]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.94 [0.7, 1.25]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.77 [0.3, 1.97]	1 study · 53 participants	Very low
Infliximab vs placebo Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.59 [0.37, 0.96]	1 study · 73 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.68 [0.29, 1.59]	1 study · 73 participants	Very low
Infliximab vs adalimumab Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.1 [0.01, 0.72]	1 study · 73 participants	Very low
Infliximab vs adalimumab Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.09 [0.01, 1.54]	1 study · 73 participants	Very low

Reviews 172

Infliximab for maintenance of medically‐induced remission in Crohn's disease

Gordon, M, Sinopoulou, V, et al. · Cochrane Database of Systematic Reviews · 2024

Gut

Thinnest evidence

Reviews 172

Infliximab for maintenance of medically‐induced remission in Crohn's disease

Prebiotics for induction and maintenance of remission in ulcerative colitis

Medical treatment of eosinophilic esophagitis

Pharmacological treatment of gastro‐oesophageal reflux in children

Vitamin D for the treatment of inflammatory bowel disease

Infliximab for medical induction of remission in Crohn's disease

Fecal transplantation for treatment of inflammatory bowel disease

Probiotics for management of functional abdominal pain disorders in children

Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage

Non‐Chinese herbal medicines for functional dyspepsia

Vedolizumab for induction and maintenance of remission in Crohn's disease

Patient education interventions for the management of inflammatory bowel disease

Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)

Remote care through telehealth for people with inflammatory bowel disease

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis

Guidewire‐assisted cannulation of the common bile duct for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis

Physical activity for treatment of irritable bowel syndrome

Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy

Stem cell transplantation for induction of remission in medically refractory Crohn’s disease

Fundoplication in laparoscopic Heller's cardiomyotomy for achalasia

Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy

Probiotics for the prevention of Hirschsprung‐associated enterocolitis

Antibiotics for the induction and maintenance of remission in ulcerative colitis

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease